NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Dollar change +0.03
Percentage change 0.41	%

Peers: MRNA SNY NVAX DVAX INBX OCGN VXRT ADMA XERS HEPA

| Held by: AVUV VTI IWM XBI VXF CALF PRFZ FNDA IWN IBB

Index	RUT	P/E	-	EPS (ttm)	-2.71	Insider Own	4.35%	Shs Outstand	54.50M	Perf Week	5.29%
Market Cap	399.48M	Forward P/E	5.89	EPS next Y	1.25	Insider Trans	0.30%	Shs Float	51.92M	Perf Month	9.04%
Enterprise Value	919.38M	PEG	-	EPS next Q	-0.10	Inst Own	66.19%	Short Float	19.28%	Perf Quarter	56.93%
Income	-131.60M	P/S	0.41	EPS this Y	469.57%	Inst Trans	4.71%	Short Ratio	7.90	Perf Half Y	-28.40%
Sales	965.40M	P/B	0.73	EPS next Y	47.06%	ROA	-8.15%	Short Interest	10.01M	Perf YTD	-23.01%
Book/sh	10.14	P/C	2.61	EPS next 5Y	-	ROE	-21.63%	52W High	15.10 -51.26%	Perf Year	-15.60%
Cash/sh	2.82	P/FCF	4.23	EPS past 3/5Y	- -	ROIC	-10.76%	52W Low	4.02 83.08%	Perf 3Y	-77.59%
Dividend Est.	-	EV/EBITDA	15.61	Sales past 3/5Y	-16.20% -1.15%	Gross Margin	29.20%	Volatility	4.40% 5.57%	Perf 5Y	-91.42%
Dividend TTM	-	EV/Sales	0.95	EPS Y/Y TTM	76.88%	Oper. Margin	-5.14%	ATR (14)	0.39	Perf 10Y	-75.92%
Dividend Ex-Date	-	Quick Ratio	3.51	Sales Y/Y TTM	-18.56%	Profit Margin	-13.63%	RSI (14)	62.82	Recom	2.33
Dividend Gr. 3/5Y	- -	Current Ratio	6.32	EPS Q/Q	588.34%	SMA20	10.16%	Beta	1.99	Target Price	13.50
Payout	-	Debt/Eq	1.22	Sales Q/Q	-26.03%	SMA50	16.74%	Rel Volume	0.82	Prev Close	7.33
Employees	900	LT Debt/Eq	1.21	Earnings	May 07 AMC	SMA200	-4.18%	Avg Volume	1.27M	Price	7.36
IPO	Nov 15, 2006	Option/Short	Yes / Yes	EPS/Sales Surpr.	61.36% 1.46%	Trades		Volume	1,042,988	Change	0.41%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-30-24	Initiated	H.C. Wainwright	Buy	$15
Aug-22-24	Initiated	Rodman & Renshaw	Buy	$16
Mar-07-24	Upgrade	The Benchmark Company	Hold → Buy	$5
Nov-20-23	Resumed	JP Morgan	Underweight
Aug-29-23	Downgrade	The Benchmark Company	Buy → Hold
Apr-10-23	Upgrade	The Benchmark Company	Hold → Buy	$22
Mar-17-23	Downgrade	JP Morgan	Neutral → Underweight	$23 → $9
Nov-10-22	Downgrade	The Benchmark Company	Buy → Hold
Apr-29-22	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Jan-20-22	Upgrade	The Benchmark Company	Hold → Buy	$77
Nov-08-21	Downgrade	The Benchmark Company	Buy → Hold
May-05-21	Downgrade	Argus	Buy → Hold
Apr-07-21	Initiated	The Benchmark Company	Buy	$150
Feb-24-21	Upgrade	Chardan Capital Markets	Neutral → Buy	$112
Feb-19-21	Downgrade	Chardan Capital Markets	Buy → Neutral	$112
Jan-08-21	Downgrade	Wells Fargo	Overweight → Equal Weight	$110
Sep-14-20	Resumed	JP Morgan	Neutral	$103
Jul-31-20	Reiterated	Chardan Capital Markets	Buy	$86 → $112
Sep-12-19	Initiated	Guggenheim	Buy
Sep-04-19	Upgrade	Wells Fargo	Market Perform → Outperform

Show Previous Ratings

Jul-08-25 04:45PM	Emergent BioSolutions Secures $51.9 Million Contract Modification Award for CNJ-016 [Vaccinia Immune Globulin Intravenous (Human)] (VIGIV) as part of U.S. Biodefense Preparedness Efforts (GlobeNewswire) +6.70%
Jul-02-25 04:05PM	Emergent BioSolutions Expands NARCANDirect to Offer KLOXXADO (naloxone HCl) Nasal Spray 8 mg and Convenience Kits Amid Changes in Overdose Death Rate (GlobeNewswire) +7.73%
Jun-23-25 08:05AM	Emergent BioSolutions Secures $62.4 Million Contract Modification for BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)] to Bolster U.S. Biodefense Supply (GlobeNewswire)
Jun-20-25 08:13AM	Emergent BioSolutions Announces Addition to Russell 3000 Index (GlobeNewswire)
Jun-05-25 07:00AM	Emergent BioSolutions Supports Victoria's Voice Foundation's National Naloxone Awareness Day Efforts on June 6 to Encourage Americans to Be Prepared for Opioid Emergencies (GlobeNewswire)
09:55AM	Loading…
May-29-25 09:55AM	5 Broker-Loved Stocks Amid EU Tariff Pause & Consumer Confidence Boost (Zacks)
May-19-25 09:43AM	Zacks.com featured highlights include BrightSpring Health Services, Beyond, Air Canada, HF Sinclair and Emergent BioSolutions (Zacks)
May-16-25 10:52AM	5 Broker-Loved Stocks to Watch Amid Signs of Easing Trade Woes (Zacks) +20.95%
May-14-25 07:32AM	Emergent BioSolutions to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-08-25 09:53AM	Q1 2025 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) +34.18%
03:33AM	Emergent BioSolutions Inc (EBS) Q1 2025 Earnings Call Highlights: Strong Net Income Growth Amid ... (GuruFocus.com)
May-07-25 10:03PM	Emergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progress (Seeking Alpha)
10:01PM	Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
04:32PM	Emergent Biosolutions: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Emergent BioSolutions Reports First Quarter 2025 Financial Results (GlobeNewswire)
May-01-25 05:07PM	Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health (GlobeNewswire) -7.87%
Apr-22-25 08:00AM	Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025 (GlobeNewswire)
Apr-10-25 09:52AM	Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last? (Zacks) -9.17%
Apr-09-25 08:45AM	JAZZ Pharmaceuticals Stock Trades Near 52-Week Low: Time to Buy or Sell? (Zacks) +9.58%
Apr-08-25 12:24AM	XOMA Royalty Corporation's Preferreds Still Offer Attractive Yields With A Biotech Twist (Seeking Alpha)
Mar-31-25 08:00AM	Emergent BioSolutions Announces Stock Repurchase Program (GlobeNewswire)
Mar-26-25 10:32AM	Emergent BioSolutions: I See Further Downside Ahead In This Value Trap (SeekingAlpha) -6.00%
Mar-20-25 04:30PM	Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08 (GlobeNewswire)
08:30AM	Emergent BioSolutions: Attractive Biotech With Proven Business Clouded By Washington Funding Issues (SeekingAlpha)
08:06AM	Hikma announces Health Canada approval of KLOXXADO (naloxone HCl) Nasal Spray 8 mg (GlobeNewswire)
Mar-19-25 05:01PM	Emergent BioSolutions closes sale of Bayview facility to Syngene (SeekingAlpha)
04:30PM	Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-18-25 08:00AM	Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products (GlobeNewswire)
Mar-13-25 11:00AM	Emergent signs financial investment agreement with Swiss Rockets (Pharmaceutical Technology) -10.41%
08:29AM	Loading…
08:29AM	Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs (GlobeNewswire)
Mar-12-25 08:00AM	Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates (GlobeNewswire) +11.21%
Mar-10-25 09:14AM	Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International (GlobeNewswire)
Mar-04-25 06:59AM	Q4 2024 Emergent BioSolutions Inc Earnings Call (Thomson Reuters StreetEvents) -6.44%
02:45AM	Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript (Motley Fool)
02:05AM	Emergent BioSolutions Inc (EBS) Q4 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Mar-03-25 05:40PM	Emergent Biosolutions (EBS) Q4 Earnings Top Estimates (Zacks) -8.69%
04:45PM	Emergent Biosolutions: Q4 Earnings Snapshot (Associated Press Finance)
04:23PM	Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Feb-18-25 08:55AM	Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025 (GlobeNewswire) -14.20%
Feb-07-25 08:06AM	Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans (GlobeNewswire)
Jan-23-25 09:01AM	Emergent seeking to reverse fortunes and become a major overdose treatment player (Pharmaceutical Technology) +5.61%
Jan-16-25 08:00AM	Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA) (GlobeNewswire)
Jan-14-25 07:30AM	Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals (GlobeNewswire)
Jan-13-25 09:27AM	Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga (ansuvimab-zykl) Treatment for Ebola (GlobeNewswire)
Jan-08-25 07:45AM	Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 (GlobeNewswire)
07:30AM	Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax (Anthrax Vaccine Adsorbed) (GlobeNewswire)
Dec-30-24 05:26PM	Why Emergent BioSolutions Stock Blasted Higher Today (Motley Fool) +11.85%
Dec-16-24 08:00AM	Emergent BioSolutions Receives $50 Million Contract Option from BARDA to Procure Doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (GlobeNewswire)
Dec-03-24 06:47PM	Why Emergent BioSciences Stock Plummeted Today (Motley Fool) -5.59%
Nov-08-24 10:04AM	Emergent BioSolutions Inc (EBS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com) +7.00%
Nov-07-24 02:06PM	Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024 (Benzinga) +19.57%
01:15AM	Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript (Motley Fool)
Nov-06-24 06:20PM	Emergent Biosolutions (EBS) Q3 Earnings Beat Estimates (Zacks)
05:17PM	Emergent Biosolutions: Q3 Earnings Snapshot (Associated Press Finance)
04:49PM	Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa (GlobeNewswire)
04:05PM	Emergent BioSolutions Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:30AM	Emergent BioSolutions Appoints Dr. Simon Lowry as Chief Medical Officer and Head of Research and Development (GlobeNewswire)
Oct-23-24 07:30AM	Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024 (GlobeNewswire) -5.20%
Oct-11-24 12:33PM	Emergent BioSolutions Inc. (EBS): A Standout Among Best Performing Cheap Stocks in 2024 (Insider Monkey)
Oct-09-24 05:09PM	Emergent BioSolutions Inc (EBS) Q2 2024 Earnings Call Highlights: Navigating Challenges and ... (GuruFocus.com) -5.38%
11:09AM	Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says (Pharmaceutical Technology)
Oct-08-24 05:32PM	Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN Nasal Spray to Help Combat the Opioid Epidemic (GlobeNewswire)
Oct-02-24 07:30AM	Emergent BioSolutions Announces Closing of $100 Million Asset-Backed Loan Facility (GlobeNewswire) +8.50%
Sep-26-24 08:05AM	Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA (brincidofovir) to Support National Preparedness Efforts (GlobeNewswire) +22.56%
Sep-25-24 07:07AM	Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts (GlobeNewswire)
Sep-13-24 06:45AM	Emergent BioSolutions Announces Agreement to Settle Securities Class Action Litigation (GlobeNewswire)
Sep-12-24 08:30AM	Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga Treatment for Ebola (GlobeNewswire)
01:27AM	BlackRock Inc. Reduces Stake in Emergent BioSolutions Inc. (GuruFocus.com)
Sep-04-24 05:51PM	OHA is Administrative Agent and Sole Lender for Emergent BioSolutions Debt Refinancing (GlobeNewswire)
08:00AM	Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors (GlobeNewswire)
Sep-03-24 07:08AM	Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile (GlobeNewswire) -11.07%
Aug-30-24 09:55AM	Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine (Barrons.com) -6.73%
08:33AM	This Biotech Stock Surges As WHO Health Emergency Stirs FDA Approval (Investor's Business Daily)
08:33AM	Emergent BioSolutions Stock Storms Higher After The FDA Signs Off On Mpox Vaccine (Investor's Business Daily)
08:16AM	Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness (GlobeNewswire)
04:32AM	Emergent gains FDA approval for ACAM2000 vaccine for Mpox (Pharmaceutical Technology)
Aug-29-24 06:53PM	Emergent BioSolutions' ACAM2000 , (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions (GlobeNewswire)
Aug-21-24 11:14AM	Emergent BioSolutions finalises manufacturing site sale to Bora Pharmaceuticals (Pharmaceutical Technology) +8.82%
Aug-20-24 12:03PM	Emergent joins mpox fight with 50,000 vaccine dose donation to Africa (Pharmaceutical Technology) -20.33%
11:30AM	Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals (GlobeNewswire)
Aug-19-24 05:16PM	WHO declares mpox a public health emergency as variant emerges (Yahoo Finance Video) +12.66%
05:10PM	Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa (GlobeNewswire)
Aug-16-24 04:14PM	Emergent Leads Mpox-Tied Stock Gains as Investors Await Approval (Bloomberg) +24.02%
12:51PM	Why Emergent BioSolutions Stock Is Skyrocketing Today (Motley Fool)
09:52AM	Mpox Vaccine Makers Stock Soars After Fresh WHO Warning (Barrons.com)
Aug-07-24 02:45AM	Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript (Motley Fool) -41.99%
Aug-06-24 05:14PM	Emergent Biosolutions: Q2 Earnings Snapshot (Associated Press Finance)
05:01PM	Emergent BioSolutions Reports Second Quarter 2024 Financial Results (GlobeNewswire)
08:00AM	Emergent BioSolutions Expands NARCAN Nasal Spray Distribution Capabilities to Enhance Customer Delivery Experience Across the Country (GlobeNewswire)
Jul-31-24 09:06AM	SERB Pharmaceuticals strengthens leadership in medical countermeasures with the global acquisition of RSDL (Reactive Skin Decontamination Lotion) kit for $75 million (GlobeNewswire) +7.08%
08:53AM	Emergent BioSolutions Completes Sale of RSDL (Reactive Skin Decontamination Lotion) Kit to SERB Pharmaceuticals for $75 Million (GlobeNewswire)
Jul-25-24 01:20PM	The stock markets cruel summer is about to get much worse (MarketWatch)
Jul-24-24 07:30AM	Emergent BioSolutions Launches Opioid Emergency Preparedness 'Lay, Spray, Stay' Public Education Campaign Starring Pro Football Hall of Famer Emmitt Smith (GlobeNewswire) +10.57%
Jul-23-24 08:27AM	Emergent BioSolutions to Release Second Quarter 2024 Financial Results & Conduct Conference Call on August 6, 2024 (GlobeNewswire) +8.99%
Jul-22-24 08:00AM	Emergent BioSolutions Announces Shelf-Life Extension for NARCAN Nasal Spray in Canada (GlobeNewswire)
Jul-09-24 07:30AM	Emergent BioSolutions Continues to Drive Improved Financial Position as Part of Multi-Year Transformation Plan (GlobeNewswire) +7.26%
Jul-03-24 10:13AM	Emergent scores US medical countermeasure contracts worth over $250m (Pharmaceutical Technology)
Jul-02-24 09:43AM	Update: Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products (GlobeNewswire) +6.09%
08:13AM	Emergent BioSolutions Awarded $250+ Million in Contract Modifications to Supply U.S. Government with Four Critical Medical Countermeasure Products (GlobeNewswire)

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The firm's products include ACAM2000, BioThrax, Raxibacuma, Vaxchora, and VIGIV. Its business units include Vaccines and Anti-Infectives, Antibody Therapeutics, Devices, and Contract Development and Manufacturing. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Katkin Keith	Director	May 23 '25	Sale	6.30	7,844	49,417	86,431	May 28 04:08 PM
KEITH KATKIN	Director	May 23 '25	Proposed Sale	6.30	7,844	49,409		May 23 04:04 PM
PAPA JOSEPH C	President and CEO	May 13 '25	Buy	5.83	60,000	349,800	342,500	May 15 04:02 PM
Fowler Neal Franklin	Director	Mar 12 '25	Sale	5.83	35,000	204,050	101,100	Mar 12 06:13 PM
Zoon Kathryn C	Director	Mar 12 '25	Sale	5.73	10,000	57,300	44,482	Mar 12 06:13 PM
Fowler Neal Franklin	Director	Mar 12 '25	Proposed Sale	5.83	35,000	204,005		Mar 12 05:34 PM
Zoon Kathryn C	Director	Mar 12 '25	Proposed Sale	5.73	10,000	57,300		Mar 12 05:23 PM
DeGolyer Donald W	Director	Nov 12 '24	Sale	10.91	25,000	272,750	111,100	Nov 14 04:18 PM
White Marvin L	Director	Nov 11 '24	Sale	11.97	14,287	171,015	54,092	Nov 13 04:04 PM
DeGolyer Donald W	Director	Nov 12 '24	Proposed Sale	11.77	25,000	294,250		Nov 12 05:16 PM
White Marvin L	Director	Nov 11 '24	Proposed Sale	11.77	14,287	168,158		Nov 12 10:34 AM

Open in Screener

APVO

Aptevo Therapeutics Inc

Jul 11 • 04:00PM ET

3.00

Dollar change -0.01
Percentage change -0.33	%

Healthcare • Biotechnology • USA • NASD

APVO Aptevo Therapeutics Inc daily Stock Chart

Peers: JNJ PFE MRK LLY AMGN BMY GILD BIIB REGN VRTX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-1769.09	Insider Own	7.96%	Shs Outstand	3.22M	Perf Week	-1.32%
Market Cap	9.67M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	2.97M	Perf Month	-35.76%
Enterprise Value	11.95M	PEG	-	EPS next Q	-	Inst Own	19.98%	Short Float	5.55%	Perf Quarter	-85.00%
Income	-23.70M	P/S	-	EPS this Y	-	Inst Trans	0.62%	Short Ratio	0.07	Perf Half Y	-97.10%
Sales	0.00M	P/B	-	EPS next Y	-	ROA	-182.54%	Short Interest	0.16M	Perf YTD	-96.52%
Book/sh	-20.20	P/C	4.52	EPS next 5Y	-	ROE	-1023.93%	52W High	485.37 -99.38%	Perf Year	-98.62%
Cash/sh	0.66	P/FCF	-	EPS past 3/5Y	79.32% 80.96%	ROIC	-803.80%	52W Low	2.81 6.76%	Perf 3Y	-100.00%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.66% 19.48%	Perf 5Y	-100.00%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	97.59%	Oper. Margin	-	ATR (14)	0.79	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.67	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	34.87	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.67	EPS Q/Q	98.81%	SMA20	-12.20%	Beta	5.64	Target Price	420.00
Payout	-	Debt/Eq	-	Sales Q/Q	-	SMA50	-42.27%	Rel Volume	0.05	Prev Close	3.01
Employees	42	LT Debt/Eq	-	Earnings	May 15 BMO	SMA200	-96.22%	Avg Volume	2.38M	Price	3.00
IPO	Jul 20, 2016	Option/Short	No / Yes	EPS/Sales Surpr.	-4.28% -	Trades		Volume	126,813	Change	-0.33%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-05-18	Initiated	Ladenburg Thalmann	Buy
Oct-05-17	Resumed	Piper Jaffray	Overweight	$6

Jun-21-25 09:00AM	Aptevo announces addition of preclinical candidate APVO455 to portfolio (TipRanks)
Jun-20-25 11:30AM	Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -18.71%
08:55AM	Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers (ACCESSWIRE)
Jun-18-25 10:52AM	Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) +81.91%
08:01AM	Mipletamig Demonstrates Compelling Clinical Activity in Frontline AML (ACCESSWIRE)
08:05AM	Loading…
Jun-13-25 08:05AM	Aptevo Participating in the BIO International Convention (ACCESSWIRE) -8.16%
May-22-25 08:05AM	Aptevo Therapeutics Announces 1-for-20 Reverse Stock Split as part of Nasdaq Compliance Plan (ACCESSWIRE) -21.05%
May-15-25 08:05AM	Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig (ACCESSWIRE)
May-08-25 08:45AM	Aptevo Therapeutics Provides Program Update for Bispecific APVO711, a PD-L1 X CD40 that Combines a Checkpoint Inhibitor and Immune Activation (ACCESSWIRE) -7.69%
Apr-22-25 04:05PM	Aptevo Therapeutics Announces the Closing of $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +9.08% +6.72%
Apr-21-25 02:40PM	Aptevo Therapeutics $2.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -26.24%
Apr-04-25 04:05PM	Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -25.13% -6.71%
Apr-03-25 08:50AM	Aptevo Therapeutics $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) +44.20%
Mar-20-25 02:26PM	Aptevo Therapeutics Says Two Additional Patients In Early-Stage Leukemia Trial Achieve Remission Within 30 Days of Treatment (Benzinga) -6.09%
08:35AM	RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of Treatment (ACCESSWIRE)
08:05AM	Loading…
Mar-18-25 08:05AM	Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy (ACCESSWIRE)
Mar-06-25 08:00AM	Aptevo to Participate in March Conferences (ACCESSWIRE)
Feb-15-25 06:59PM	Aptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Feb-14-25 08:05AM	Aptevo Therapeutics Reports 2024 Financial Results And Provides A Business Update (ACCESSWIRE) -8.24%
Jan-15-25 08:00AM	Aptevo's Peter Pavlik, PhD, Chairing Session on 'Bi and Multispecific Biologics' at Cambridge Healthcare Institute's Pep Talk 2025 (ACCESSWIRE)
Dec-12-24 12:50PM	Aptevo Therapeutics Announces Exercise of Warrants for $6.2 Million Gross Proceeds (ACCESSWIRE) -43.76%
09:00AM	100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial (ACCESSWIRE)
Dec-04-24 08:35AM	Bispecific Antibody, APVO442, Differentiated to Treat Prostate Cancer with Precision Tumor Targeting and Reduced Risk of Side Effects (ACCESSWIRE) +15.01%
Nov-29-24 09:55AM	Aptevo Therapeutics Announces 1-for 37 Reverse Stock Split As Part of Nasdaq Compliance Plan (ACCESSWIRE) -18.88%
Nov-26-24 08:35AM	Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at Presentation (ACCESSWIRE) +9.20%
Nov-22-24 08:35AM	Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm (ACCESSWIRE) +15.33%
Nov-20-24 08:35AM	First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies (ACCESSWIRE) +16.05%
Nov-11-24 08:15AM	First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor Trial (ACCESSWIRE)
Nov-07-24 08:05AM	Aptevo Therapeutics Reports 3Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE) +19.77%
Oct-29-24 08:05AM	Aptevo Therapeutics and Alligator Bioscience to Present Additional Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at SITC 2024 (ACCESSWIRE) +27.95%
04:05PM	Loading…
Sep-18-24 04:05PM	Aptevo Therapeutics Announces Closing of $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -19.55% +6.93%
Sep-16-24 08:05PM	Aptevo Therapeutics Announces $3.0 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -7.02% -38.00%
08:20AM	Alligator Bioscience and Aptevo Therapeutics Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study (ACCESSWIRE)
08:05AM	Aptevo Therapeutics and Alligator Bioscience Announce Data from Phase 1 ALG.APV-527 Monotherapy Trial Showing 60% of Evaluable Patients Achieved Stable Disease in Solid Tumor Study (ACCESSWIRE)
Sep-13-24 08:20AM	Alligator Bioscience and Aptevo Therapeutics to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types at ESMO Congress 2024 (ACCESSWIRE)
08:05AM	Aptevo Therapeutics and Alligator Bioscience to Present Positive Interim Phase 1 Data Evaluating ALG.APV-527 Monotherapy in Multiple Solid Tumor Types, at ESMO Congress 2024 (ACCESSWIRE)
Aug-13-24 08:05AM	Phase 1b/2 'RAINIER' Frontline Acute Myeloid Leukemia (AML) Trial Initiated (ACCESSWIRE) -8.57%
Aug-08-24 08:05AM	Aptevo Therapeutics Reports 2Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
Jul-01-24 04:20PM	Aptevo Therapeutics Announces Closing of $2.75 Million Offering (ACCESSWIRE) +9.15% -10.78%
Jun-28-24 09:20AM	Aptevo Therapeutics Announces $2.75 Million Offering Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -40.57%
Jun-17-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -20.53%
Jun-03-24 08:05AM	Aptevo Participating in the BIO International Convention (ACCESSWIRE) +10.58%
May-14-24 08:05AM	Aptevo Therapeutics Presenting at The Protein & Antibody Engineering Summit, Boston, MA (ACCESSWIRE)
May-08-24 12:54PM	APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024 (InvestorPlace) -11.64%
08:05AM	Aptevo Therapeutics Reports 1Q 2024 Financial Results and Provides a Business Update (ACCESSWIRE)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace) +17.71%
Apr-16-24 12:47PM	Aptevo (APVO) Stock Plummets 79% in a Week: Here's Why (Zacks)
Apr-15-24 04:05PM	Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering (ACCESSWIRE) -7.35%
Apr-11-24 08:15AM	Why Is Aptevo Therapeutics (APVO) Stock Down 56% Today? (InvestorPlace) -60.08%
08:00AM	Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering (ACCESSWIRE)
Apr-10-24 09:00AM	Aptevo Therapeutics Provides Pipeline Update (ACCESSWIRE) -26.38%
Mar-18-24 06:00AM	Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference (ACCESSWIRE) -8.12%
Mar-07-24 08:55AM	Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 (ACCESSWIRE)
Mar-05-24 01:51PM	APVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023 (InvestorPlace) -8.55%
08:05AM	Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update (ACCESSWIRE)
Mar-04-24 09:00AM	Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan (ACCESSWIRE) -13.72%
Nov-14-23 08:05AM	Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update (ACCESSWIRE) +6.82%
Nov-01-23 07:45AM	Aptevo to Present at Bio-Europe Conference (ACCESSWIRE)
Aug-10-23 08:05AM	Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update (ACCESSWIRE) -9.68%
Aug-06-23 07:14AM	10 Oversold Value Stocks To Buy (Insider Monkey)
Aug-04-23 06:40PM	Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering (ACCESSWIRE) -10.19%
Aug-01-23 10:15PM	Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering (ACCESSWIRE) -5.77% -38.30%
Jul-30-23 02:17PM	7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes (InvestorPlace)
Jul-18-23 08:05AM	Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML (ACCESSWIRE) -23.24%
May-11-23 08:05AM	Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update (ACCESSWIRE)
Apr-01-23 08:51AM	Aptevo Therapeutics Full Year 2022 Earnings: EPS Beats Expectations (Simply Wall St.)
Mar-30-23 07:45AM	Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update (ACCESSWIRE)
07:30AM	Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding (ACCESSWIRE)
Mar-29-23 10:13AM	12 Cheap Healthcare Stocks to Buy in 2023 (Insider Monkey) +6.88%
Mar-03-23 06:57PM	The Top 7 Growth Stocks in Biotech (InvestorPlace)
Feb-13-23 08:05AM	Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial (ACCESSWIRE)
Jan-09-23 08:05AM	Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors (ACCESSWIRE) +6.42%
Dec-12-22 09:54AM	Aptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit Rate (Benzinga) +12.58%
07:35AM	100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML) (ACCESSWIRE)
Nov-10-22 08:05AM	Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights (ACCESSWIRE)
Nov-09-22 08:05AM	Alligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer Therapeutics (ACCESSWIRE)
Nov-03-22 09:06AM	Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition (ACCESSWIRE)
Sep-19-22 08:45AM	Alligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 IND (ACCESSWIRE)
Aug-11-22 08:05AM	Aptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights (ACCESSWIRE)
Jun-09-22 08:05AM	Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia (ACCESSWIRE) -14.44%
May-12-22 08:05AM	Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights (ACCESSWIRE) +11.26%
Apr-12-22 08:05AM	APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting (ACCESSWIRE)
Mar-29-22 08:05AM	Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia (ACCESSWIRE)
Mar-24-22 08:05AM	Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update (ACCESSWIRE) +32.82%
Feb-09-22 08:05AM	Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update (ACCESSWIRE) +5.62%
Jan-21-22 08:05AM	Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022 (ACCESSWIRE) -6.51%
Dec-15-21 08:05AM	Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication" (ACCESSWIRE)
Dec-10-21 05:38PM	Towercrest Capital Management Buys Aptevo Therapeutics Inc, PowerShares QQQ Trust Ser 1, ... (GuruFocus.com) -5.13%
Nov-23-21 08:05AM	Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia (ACCESSWIRE) +162.81%
07:59AM	Aptevo Therapeutics Stock More Than Doubles After Leukemia Study News (Investing.com)
Nov-15-21 08:05AM	Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting (ACCESSWIRE) -16.49%
Nov-12-21 08:05AM	Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights (ACCESSWIRE) -8.71%
Nov-11-21 04:45PM	Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021 (ACCESSWIRE)
08:30AM	Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting (ACCESSWIRE)
Nov-02-21 09:00AM	BriaCell Appoints Renowned Pharmaceutical Veteran Jane Gross, Ph.D. to its Board of Directors (GlobeNewswire)
Oct-27-21 08:05AM	Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021 (ACCESSWIRE)
Oct-26-21 08:05AM	Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436 (ACCESSWIRE)
Sep-28-21 08:05AM	Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging (ACCESSWIRE)
Aug-17-21 08:05AM	Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome (ACCESSWIRE)
Aug-12-21 08:05AM	Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights (ACCESSWIRE) -6.86%

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

EBS

Emergent Biosolutions Inc

APVO

Aptevo Therapeutics Inc

Upgrade your FINVIZ experience